Amgen and its subsidiary Onyx Pharmaceuticals, Inc. recently announced that it has submitted applications to both US and EU health regulators for approval of Kyprolis (carfilzomib) for treatment of multiple myeloma. The companies said that they have submitted a supplemental New Drug Application (sNDA) to the US Food and Drug …